Choosing the Right Drug Name How to Increase Your Chances for Approval

Quantity Discounts
1 - 9999
1 - 9999
1 - 9999

The FDA can shut down your next promising product due to nothing more than a single letter of its name. They already reject 40% of proposed drug names. How can you up your odds?

You’ve invested in the bench science, locked down the clinical trial data and have pulled together the application ― all you need now is a hot product name.

But that should be a snap. Consult a Latin dictionary, hold an employee naming contest, convene a brainstorming session ... you’ll have your new name in three, four months tops.


Wrong, wrong, wrong. In truth, such methods are recipes for disaster, says brand consultant Jeff Gregory. He ought to know. He was in on the naming of Viagra®, Epogen®, Ambien®, Restasis® and many other blockbuster drugs.

Mark your calendar for Thursday, Nov. 12, 2009, when Gregory takes 90 minutes out of his busy schedule to initiate you into the secrets of drug-naming.

You’ll discover:

  • How one wrong letter can trigger FDA action, adding years and millions of extra dollars in expenses to your product launch
  • Why naming contests and brainstorming can actually lead to spending more on drug-naming consultants
  • The top 5 deal-killers in drug naming ― and how to steer clear of them
  • How close you can come to the line ― without crossing it ― in descriptive and benefit-driven drug naming
  • What to not even consider in drug naming

Gregory will debunk the urban legends about what brand names really mean ... how the X, Y and Z craze began ... how to position a brand in terms of the target audience, not the science ... and that’s just the beginning. You’ll learn:

  • Best practices for approaching a brand-name development project
  • Why the last FDA nomenclature director got the nickname Dr. Boring
  • Latest news from the FDA’s Proprietary Name Pilot Program
  • And why drug naming is so much harder than it looks

There are reasons that savvy drug and biologic companies spend $1 million ... $2 million ... even $3 million naming a new drug ... why they bring naming consultants on board at the earliest stages of clinical testing ... why the FDA rejects 40% of proposed drug names each year.

It costs you millions when the FDA delays your launch campaign. That’s not a risk worth taking — especially when you can pick the brain of one of the brainiest drug-namers around. Because it’s web-based, this 90-minute session is totally interactive — meaning you get your every question answered by the time you log off.

As many staffers may participate from one location as you like, all for one low registration fee. So don’t skimp — make sure every employee on your product development team participates, including:

  • Sales and marketing personnel
  • Compliance officers
  • Regulatory and legislative affairs professionals
  • R&D staff
  • Executive management
  • General and corporate counsel
  • Risk management specialists
  • Strategic planning and business development staff
  • Consultants and service providers
  • Personnel new to the industry

Jeff Gregory is CEO and chief brand strategist at Brand Counsel, LLC. His firm brands exclusively in the life science and technology markets worldwide. A 23-year veteran of the drug and device industries, Mr. Gregory has been involved in blockbuster drug launches including Viagra®, Epogen®, Ambien®, Restasis® and many more. Mr. Gregory began his career in technology marketing and brand positioning with AT&T’s BellSouth and was previously managing director of The Brand Institute.

Register now!

Date: Thursday, Nov. 12, 2009
Location: Your office or conference room (no need to travel!)
Time: 1:30 p.m. – 3:00 p.m. EST
  12:30 p.m. – 2:00 p.m. CST
  11:30 a.m. – 1:00 p.m. MST
  10:30 a.m. – 12:00 p.m. PST
  6:30 p.m. – 8:00 p.m. GMT

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Check your local time against the times above. (Washington, D.C. is representative of Eastern time.)

Can't make the scheduled date and time? See the 24/7 ENCORE option described below.

Four Cost-Effective Tuition Options
All participants of the live session are eligible to receive a certificate of attendance.

Payment is required by the date of the webinar. We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Webinar registrations may not be cancelled. Registrants may substitute the 24/7 ENCORE™ audio presentation or the CD/transcript package for the live webinar at any time. Please contact customer service to make any substitutions. No shows will automatically be shipped the CD/transcript package, including the speaker's presentation. (Additional shipping and handling charges for the CD/transcript package may apply.)

Interested in Becoming a Speaker?
We're always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.